Medpace beats Q3 estimates but guides below on revenue

Medpace Holdings (MEDP) reported Q3 adjusted earnings of $4.84 per share, beating estimates by $0.40, with revenue of $716.0 million, up 8.5% YoY. Full-year 2026 revenue guidance of $2.835B-$2.855B fell below analyst consensus, causing shares to drop 1.9% in after-hours trading. The company also announced a new $1.0B stock repurchase program.

Original reporting
Published Oct 21, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MEDP
Bearish
high confidence
Mentioned
$MEDP
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MEDPBearishMed
01

Why it matters

Traders should focus on the guidance gap versus consensus (revenue midpoint below expectations) and whether the stronger EPS outlook and backlog growth can stabilize the stock after the initial after-hours selloff.

02

Market read

This is a classic beat-and-miss setup: earnings beat supports the story, but the revenue guidance midpoint below consensus is the immediate driver of negative sentiment.

03

What to watch

Net new business awards ($873.4M) and backlog ($3.167B) increased, suggesting revenue visibility may improve later in the year even if the current full-year midpoint is slightly conservative.

Relevance 8/10Novelty 7/10Timing: after-hours reaction following the Q3 results and full-year guidance update

Background

Medpace is a clinical contract research organization, and the article reports its Q3 results plus full-year 2026 guidance and a new $1.0B buyback authorization.

Company-level read

Ticker impact

$MEDPBearishHigh confidence
Context

Medpace (MEDP) beat Q3 EPS and revenue estimates but guided full-year revenue to a midpoint below consensus, driving after-hours weakness.

Expected impact

Likely downside pressure as investors reprice full-year revenue growth expectations around the below-consensus midpoint.

Evidence & confidence

The article cites a Q3 beat plus a full-year revenue midpoint of $2.845B versus $2.852B consensus, and notes shares slipped 1.9% after hours.

Market effects

CRO peers may see read-across on demand durability and pricing power if investors treat the revenue guide as a signal for industry growth.

Limited direct regional spillover; impact is primarily single-name within US healthcare services/CROs.

Modest, as CRO guidance affects global clinical outsourcing sentiment but the article provides no cross-border policy or macro catalyst.

Counterpoint

The company still raised/maintained profitability metrics (EBITDA margin up, EPS midpoint above consensus) and reported strong net new awards and backlog growth, which could offset the revenue guide disappointment.

Key entities

  • Medpace Holdings Inc

    Reported Q3 adjusted EPS and revenue above estimates, but guided full-year revenue below consensus midpoint.

  • Board of Directors

    Approved a new $1.0B stock repurchase authorization effective October 20, 2026 through December 31, 2028.

Related articles

$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.